GENE Genetic Technologies Limited: Price-to-Projected Revenue Ratio

Genetic Technologies aims to integrate predictive PRS tests into the standard of care for cancer and cardiac pathology prevention. Capitalization growth is driven by the expansion of AI diagnostics in the US and Australia, supported by high margins on consumables. However, the lack of stable cash flow leaves the company dependent on the pace of technology adoption. The forward P/S trend clearly illustrates market expectations, with the value fixed at 0.70.

GTG Labs - GENE Market Cap to Future Revenue Ratio (period 07/04/2022 - 10/26/2024)

Analytical breakdowns for Genetic Technologies

- current price and projected stock value:

Stock Price Genetic Technologies Limited|GENE - Average Forecast Price

- company stock capitalization data:

Market Value Genetic Technologies Limited|GENE - Business Value

- book value of equity indicators:

Book Value per Share Genetic Technologies|GENE - Total Stockholders' Equity|Market Cap to Net Assets Ratio gtglabs.com|GENE - Aggregate Business Assets

- company total debt and liquidity indicators:

Total Debt to Capital Genetic Technologies|GENE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Genetic Technologies Limited|GENE - Company Total Debt|Debt to Book Value Genetic Technologies Limited|GENE - Company Long-Term Loans and Borrowings|Company Current Liabilities Genetic Technologies|Quick Ratio gtglabs.com

- financial results and valuation multiples details:

GENE - Company Net Income|Projected Future Earnings Genetic Technologies|GENE - Price to Earnings Ratio|Forward P/E Multiple Genetic Technologies Limited|GENE - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genetic Technologies Limited|GENE - Operating profit before amortization|Earnings per share for the last twelve months Genetic Technologies|GENE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months gtglabs.com|GENE - Earnings per share growth in current year|Net earnings per share growth forecast for next year Genetic Technologies

- revenue and sales details:

GENE - Company Total Revenue|Projected Sales Volume Genetic Technologies Limited|GENE - Price-to-Revenue Multiple|Forward P/S Multiple Genetic Technologies Limited

Analysis of all company metrics:GTG Labs (GENE)

The forward P/S ratio determines the market value of an asset relative to projected sales volume, making it possible to identify hidden business degradation masked by a low price. Analyzing the forward price-to-sales ratio helps assess the scaling efficiency of Genetic Technologies (GENE) as a healthcare system partner implementing genetic testing for oncology risk diagnostics to avoid a value trap during capital freezes.

Key competitors

Forward P/S Multiple A (Agilent)|Quest Diagnostics Inc. (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS (Exact Sciences Inc.) - Market Cap to Projected Revenue|RVTY: Forward P/S Multiple|Market Cap to Future Revenue Ratio bio-rad.com (BIO)|Forward Price-to-Revenue Multiple NNNN|SHC (Sotera Health Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple QDEL|Market Cap to Expected Sales Ratio OPKO Health Corp.|Forward P/S Multiple CDNA (CareDx, Inc)|MRVI - Forward Price-to-Revenue Multiple|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Standard BioTools Inc)|CTKB (Cytek Bio) - Forward Price-to-Revenue Multiple|OSUR: Price to Expected Revenue Ratio|XGN (Exagen Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio mdxhealth.com MDXH|Forward P/S Multiple LUCD|Forward Price-to-Revenue Multiple prenetics.com PRE|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Forward Price to Sales TRIB|PRPH - Price-to-Projected Revenue Ratio|AIMD (ainos.com) - Market Cap to Projected Revenue|Co-Diagnostics (CODX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Heart Test Laboratories, Inc. (HSCS)|Price-to-Projected Revenue Ratio Biomerica, Inc|Price-to-Projected Revenue Ratio CDIO|Price-to-Projected Revenue Ratio Onconetix, Inc. (ONCO)|VRAX - Market Cap to Future Revenue Ratio|Forward P/S Multiple BJDX (Bluejay Diagnostics, Inc.)|Projected Price to Revenue Aspira Women's Health, Inc.|Accelerate Diagnostics, Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio CENTOGENE CNTG|ENZ: Forward P/S Multiple|Market Cap to Future Revenue Ratio Fresh2 Group (FRES)|Price-to-Projected Revenue Ratio 23andMe|Psychemedics Corp. (PMD) - Market Cap to Expected Sales Ratio